| Document and Entity Information | Sep. 23, 2021 |
| Cover [Abstract] | |
| Amendment Flag | true |
| Entity Central Index Key | 0001707502 |
| Document Type | 8-K/A |
| Document Period End Date | Sep. 23, 2021 |
| Entity Registrant Name | Solid Biosciences Inc. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-38360 |
| Entity Tax Identification Number | 90-0943402 |
| Entity Address, Address Line One | 141 Portland Street |
| Entity Address, Address Line Two | Fifth Floor |
| Entity Address, City or Town | Cambridge |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02139 |
| City Area Code | (617) |
| Local Phone Number | 337-4680 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock $0.001 par value per share |
| Trading Symbol | SLDB |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | true |
| Amendment Description | As previously reported in a Current Report on Form 8-K (the “Original 8-K”) filed on September 23, 2021 (the “Disclosure Date”), on the Disclosure Date, Solid Biosciences Inc. (the “Company”) reported 1.5-year functional data and patient-reported outcome measures for patients four through six in the Company’s ongoing IGNITE DMD Phase I/II clinical trial of SGT-001, all of whom received 2E14 vg/kg of SGT-001 manufactured using the Company’s first-generation manufacturing process. In the Original 8-K, the Company’s press release issued on the Disclosure Date and the presentation at the World Muscle Society 2021 Virtual Congress on the Disclosure Date, the percent predicted forced vital capacity (“FVC”) disclosed for patient five contained a numerical error which is corrected in this Amendment to Form 8-K. |
